Vigil Neuroscience price target lowered to $16 from $17 at Guggenheim
PremiumThe FlyVigil Neuroscience price target lowered to $16 from $17 at Guggenheim
3M ago
Vigil Neuroscience sees cash runway into 2026
Premium
The Fly
Vigil Neuroscience sees cash runway into 2026
3M ago
Vigil Neuroscience reports Q2 EPS (52c), consensus (55c)
Premium
The Fly
Vigil Neuroscience reports Q2 EPS (52c), consensus (55c)
3M ago
Vigil Neuroscience Advances IGNITE Trial, Eyes Accelerated Approval
PremiumCompany AnnouncementsVigil Neuroscience Advances IGNITE Trial, Eyes Accelerated Approval
4M ago
Vigil Neuroscience updates clinical development strategy for iluzanebart in ALSP
Premium
The Fly
Vigil Neuroscience updates clinical development strategy for iluzanebart in ALSP
4M ago
Vigil Neuroscience price target raised to $23 from $22 at Wedbush
Premium
The Fly
Vigil Neuroscience price target raised to $23 from $22 at Wedbush
4M ago
Vigil says interim IGNITE Phase 2 data demonstrate VGL101 potential for ALSP
PremiumThe FlyVigil says interim IGNITE Phase 2 data demonstrate VGL101 potential for ALSP
7M ago
Vigil Neuroscience’s Funding Peril: Navigating Market Turbulence in Equity Capital Raises
Premium
Company Announcements
Vigil Neuroscience’s Funding Peril: Navigating Market Turbulence in Equity Capital Raises
8M ago
Vigil Neuroscience sees cash runway into 2H25
Premium
The Fly
Vigil Neuroscience sees cash runway into 2H25
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100